• STAT+: Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority

    12 days ago - By STAT

    Everyone, and how are you today? A dank cloudy cover greeted us this morning, but we are ignoring the gloom by keeping busy. After all, there is much to be done. There are deadlines to meet, a variety of reading material to digest, and calls to make. We trust you can relate. So please join us as we fortify ourselves with more cups of stimulation - we are back to blueberry cobbler - and get started. Hope you conquer the world and accomplish much. And of course, be in touch....
    Over the last six years, a venture capital team run by Bayer invested roughly $1.5 billion into small biotech...
    Read more ...